Literature DB >> 10378340

Possibilities and restriction of isotopic lymphography for the assessment of therapeutic effects in lymphedema.

A P Pecking1.   

Abstract

Whatever the results are, we must keep in mind that the method used must be safe, simple, reproductive, quite physiological. The RNL with distal registration during 40 min give more precise and reliable informations particularly in transient or permanent lymphatic dysfunctions. This should be the protocol used for the assessment of the lymphatic function and the treatment efficacy. The RNL with nodal uptake registration is totally related to the lymphatic transport from the extremities and the exercise applied. When performed by well trained physicians concerned with the lymphatic physiology and informed of all factors interfering with the results, the quantitative functional lymphoscintigraphy is really giving objective and reproductive parameters to evaluate a treatment efficacy (decongestive physiotherapy, surgery, drugs) in lymphedemas useful to assess new lymphotonic treatments.

Entities:  

Mesh:

Year:  1999        PMID: 10378340

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  3 in total

1.  Primary lymphedema tarda in an 88-year-old African-American male.

Authors:  Ahmed Faraz Aslam; Ahmad Kamal Aslam; Muhammad Umair R Qamar; Robert Levey
Journal:  J Natl Med Assoc       Date:  2005-07       Impact factor: 1.798

2.  Giant elephantiasis neuromatosa in the setting of neurofibromatosis type 1: A case report.

Authors:  Giovanni Ponti; Giovanni Pellacani; Davide Martorana; Victor Desmond Mandel; Pietro Loschi; Annamaria Pollio; Annarita Pecchi; Cristina Dealis; Stefania Seidenari; Aldo Tomasi
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

3.  Significance of popliteal lymph nodes visualization during radionuclide lymphoscintigraphy for lower limb lymphedema.

Authors:  Ahmed Abdel-Samie Kandeel; Jehan Ahmed Younes; Ahmed Mohamed Zaher
Journal:  Indian J Nucl Med       Date:  2013-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.